EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Down 6.4% in November

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) was the target of a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 9,250,000 shares, a drop of 6.4% from the November 15th total of 9,880,000 shares. Based on an average trading volume of 855,700 shares, the short-interest ratio is currently 10.8 days.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a research note on Saturday, September 21st. Chardan Capital upped their price objective on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, December 5th. Scotiabank started coverage on EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 target price on the stock. Finally, Robert W. Baird decreased their price target on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.71.

EyePoint Pharmaceuticals Trading Up 5.4 %

NASDAQ EYPT opened at $8.02 on Wednesday. The firm’s fifty day moving average price is $9.78 and its two-hundred day moving average price is $9.14. EyePoint Pharmaceuticals has a 1 year low of $7.21 and a 1 year high of $30.99. The firm has a market capitalization of $547.37 million, a P/E ratio of -4.01 and a beta of 1.45.

Institutional Trading of EyePoint Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. lifted its holdings in shares of EyePoint Pharmaceuticals by 68.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after buying an additional 4,172 shares in the last quarter. Greenwich Wealth Management LLC raised its stake in EyePoint Pharmaceuticals by 8.3% in the third quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock valued at $93,000 after purchasing an additional 900 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of EyePoint Pharmaceuticals by 271.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock valued at $95,000 after purchasing an additional 7,953 shares during the last quarter. Cyndeo Wealth Partners LLC bought a new stake in EyePoint Pharmaceuticals during the 3rd quarter worth approximately $100,000. Finally, Arizona State Retirement System boosted its holdings in EyePoint Pharmaceuticals by 9.7% in the second quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $115,000 after acquiring an additional 1,171 shares during the last quarter. Institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.